Further studies regarding serum PGRN should be conducted to determine whether serial follow-up of PGRN levels could be predictive of breast cancer recurrence during adjuvant hormonal treatment and whether PGRN levels can be altered and predictive of prognosis after neoadjuvant treatment compared to PGRN levels pre-neoadjuvant treatment. This evidence concerns the gene GRN and breast cancer.